Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immunic ( (IMUX) ) has provided an announcement.
On January 5, 2026, Immunic, Inc. received approval to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective at the opening of trading on January 7, 2026, while continuing to trade under the symbol IMUX. The move follows a June 27, 2025 notice that Immunic had fallen out of compliance with Nasdaq’s $1.00 minimum bid price requirement and had not remedied the deficiency by the December 24, 2025 deadline; the transfer grants the company an additional 180-day grace period, until June 22, 2026, to lift its share price back above $1.00 for at least 10 consecutive business days or face potential delisting, and Immunic has informed Nasdaq it will seek to implement a reverse stock split if needed to regain compliance.
The most recent analyst rating on (IMUX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.
Spark’s Take on IMUX Stock
According to Spark, TipRanks’ AI Analyst, IMUX is a Neutral.
The score is primarily weighed down by weak financial performance (no revenue, heavy losses, and significant cash burn with worsening free cash flow) and continued technical weakness (bearish trend and momentum). Valuation offers limited support because the company is loss-making (negative P/E) and pays no dividend.
To see Spark’s full report on IMUX stock, click here.
More about Immunic
Immunic, Inc. is a publicly traded biotechnology company whose common stock is listed on Nasdaq and trades under the ticker symbol IMUX.
Average Trading Volume: 1,387,502
Technical Sentiment Signal: Sell
Current Market Cap: $76.65M
For detailed information about IMUX stock, go to TipRanks’ Stock Analysis page.